Coeptis Therapeutics (NASDAQ:ZSQR) Trading Up 10% – Still a Buy?

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) shot up 10% during trading on Friday . The stock traded as high as $9.16 and last traded at $8.98. 228,731 shares traded hands during mid-day trading, an increase of 28% from the average session volume of 179,290 shares. The stock had previously closed at $8.16.

Coeptis Therapeutics Price Performance

The firm has a market cap of $461.84 million, a P/E ratio of -3.56 and a beta of -0.09. The firm’s fifty day simple moving average is $12.21 and its 200 day simple moving average is $13.48. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.16 and a current ratio of 3.25.

Coeptis Therapeutics (NASDAQ:ZSQR) last issued its earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share (EPS) for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.The firm had revenue of $0.11 million during the quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Marshall Wace LLP purchased a new position in shares of Coeptis Therapeutics in the fourth quarter valued at $259,000. Yorkville Advisors Global LP bought a new position in Coeptis Therapeutics during the third quarter valued at $140,000. State Street Corp lifted its position in Coeptis Therapeutics by 35.0% during the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after purchasing an additional 6,962 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after buying an additional 4,721 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC grew its stake in shares of Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after buying an additional 2,500 shares in the last quarter. 13.88% of the stock is currently owned by institutional investors.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.